How to navigate the regulatory requirements for drug repurposing projects

Navigating the complex regulatory landscape for drug repurposing requires a unique strategic approach that leverages existing safety profiles while addressing new indications. Unlike first-in-class development, these projects demand a nuanced understanding of how agencies evaluate new uses for approved or investigational products, balancing risk mitigation with accelerated timelines. Success in this domain relies on early engagement with regulators to align the development strategy with specific pathways that facilitate faster access to patients.

Leveraging Existing Safety Data to Reduce Burden

The most significant advantage of drug repurposing is the pre-existing knowledge regarding the molecule's safety and pharmacokinetic properties. Regulators generally recognize that the toxicology and clinical trial data generated for the original indication provide a substantial foundation for the new indication, often allowing for a reduction in the scope of preclinical studies or the number of required Phase II patients. However, this benefit is not automatic; it must be explicitly demonstrated through a robust Justification of Use of Existing Data (JUED) strategy. Teams must meticulously map the known adverse events to the new therapeutic area to ensure that any identified risks do not outweigh the potential benefits in the target population.

Defining the Regulatory Pathway Early

One of the most common pitfalls in repurposing projects is selecting a regulatory pathway prematurely without fully understanding the nuances of the new mechanism of action or patient population. Whether the goal is to obtain a supplement to an existing approval, an indication change, or a brand new New Drug Application (NDA) for a new indication, the pathway dictates the timeline, cost, and evidentiary requirements. It is crucial to conduct a thorough feasibility study that considers the specific disease state, the severity of the condition, and the current standard of care. For highly unmet medical needs, the FDA may consider a Breakthrough Therapy designation or Fast Track status, which can provide significant flexibility in clinical trial design and review processes.

Tailoring Clinical Trial Designs for New Indications

While the safety profile is inherited, the clinical trial design for the new indication must be rigorously tailored to address efficacy and safety in the specific context of the new disease. The primary endpoint selection is often critical; if the new indication lacks a validated surrogate marker, the trial may need to focus on clinically meaningful outcomes, which can be resource-intensive. Furthermore, the inclusion criteria must be carefully constructed to ensure that the patient population is homogeneous enough to detect a signal but diverse enough to reflect real-world usage. Special attention must be paid to the comparison control; if an established standard of care exists for the new indication, a head-to-head comparison may be necessary to prove superiority or non-inferiority. In cases where no standard of care exists, a placebo-controlled trial might be justified, but this requires a compelling ethical rationale and strong support for the potential benefit.

Managing Interaction and Safety Signals

A critical aspect of repurposing is the potential for drug-drug interactions (DDIs) with other medications commonly prescribed for the new indication. Since the repurposed drug may be used in conjunction with different therapeutic classes than in its original context, a comprehensive DDI assessment is mandatory. Regulators will scrutinize any new safety signals that emerge specifically in the new patient population, such as organ toxicity exacerbated by concurrent treatments for the new disease. The labeling for the new indication must accurately reflect these risks, including updated warnings, precautions, and contraindications. Proactive communication with the FDA regarding any unexpected safety findings during the development phase is essential to maintain trust and avoid regulatory hold on the program.

Post-Market Commitments and Lifecycle Management

The journey of a repurposed drug does not end with regulatory approval; it extends into post-market surveillance and lifecycle management. Regulators expect sponsors to have a robust plan for pharmacovigilance to monitor long-term safety and efficacy in the new indication. This includes establishing a system to collect and report adverse events promptly and conducting ongoing studies to gather more long-term safety data. Additionally, the lifecycle of a repurposed product may involve updating the package insert with new information based on accumulated real-world evidence. Staying agile and prepared to modify the approved labeling as new data emerges is a hallmark of successful regulatory navigation in repurposing projects.

To ensure full compliance and strategic alignment throughout the repurposing lifecycle, sponsors should adhere to the following critical operational steps:

  1. Initiate pre-IND meetings to clarify the regulatory classification of the new indication.
  2. Compile a comprehensive Justification of Use of Existing Data (JUED) dossier.
  3. Conduct specific drug-drug interaction studies relevant to the new patient population.
  4. Select primary endpoints that are clinically meaningful for the target disease state.
  5. Establish robust post-marketing commitment plans for pharmacovigilance.
  6. Engage with regulatory agencies on labeling changes as real-world evidence accumulates.
  7. Monitor and adapt to evolving regulatory guidance documents related to repurposing.

Related reading